Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,866 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics in Healthy Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCT05106309
View directory record Official record
Conditions
Schizophrenia
Interventions
10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

NCT04742517
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

NCT06111521
View directory record Official record
Conditions
Healthy
Interventions
LY3537982, Digoxin, Rosuvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143
View directory record Official record
Conditions
Healthy Participants
Interventions
Darigabat, Carbamazepine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

NCT04866225
View directory record Official record
Conditions
Healthy Participants
Interventions
Oral [14C]PF-06865571, Oral PF-06865571, IV [14C]PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

NCT02300025
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glasdegib Absolute Bioavailability Study

NCT03270878
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Glasdegib Oral Tablet, Glasdegib IV infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 11, 2026, 6:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

NCT02018510
View directory record Official record
Conditions
Healthy, HIV
Interventions
1 mg/kg, single dose IV administration of 3BNC117, 3 mg/kg, single dose IV administration of 3BNC117, 10 mg/kg, single dose IV administration of 3BNC117, 30 mg/kg, single dose IV administration of 3BNC117, 10 mg/kg, two doses IV of 3BNC117, 30 mg/kg, two doses IV of 3BNC117
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib and Rifampin in Healthy Participants

NCT01908582
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, Rifampin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 11, 2026, 6:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 11, 2026, 6:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

NCT07219940
View directory record Official record
Conditions
Healthy Subjects, Exosome, Targeted Therapy
Interventions
SOB100
Drug
Lead sponsor
Shine-On Biomedical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

NCT00404274
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Warfarin oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

NCT06921590
View directory record Official record
Conditions
Pharmacokinetics, Neurology
Interventions
AL001, Lithium Carbonate Capsule
Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects

NCT01979185
View directory record Official record
Conditions
Healthy
Interventions
Simvastatin, SSP-004184SS
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT03482648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

NCT04470778
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib in Healthy Participants

NCT02672423
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib Capsules (Reference Formulation), Abemaciclib Tablet (Test Formulation)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

NCT05806359
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danicamtiv, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

NCT01725594
View directory record Official record
Conditions
Dyslipidemia
Interventions
CAT 2003, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 11, 2026, 6:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

NCT01520896
View directory record Official record
Conditions
Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions
NKTR-118, Ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 11, 2026, 6:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT06610279
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 11, 2026, 6:26 PM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects

NCT01340183
View directory record Official record
Conditions
Healthy
Interventions
AZD5099, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 11, 2026, 6:26 PM EDT